
These are some companies that might be interested in the results from the first Dog Years study.

# Global Arthritis Drug Pipeline

## Rheumatoid Arthritis (RA) Pipeline

|Drug Name|Company|Mechanism of Action|Development Phase|Target|
|---|---|---|---|---|
|Olokizumab|R-Pharm|IL-6 inhibitor|Phase III|IL-6|
|Filgotinib|Gilead/Galapagos|JAK1 inhibitor|Approved in EU/Japan, Phase III in US|JAK1|
|Fenebrutinib|Roche/Genentech|BTK inhibitor|Phase III|BTK|
|Otilimab|GSK|GM-CSF inhibitor|Phase III|GM-CSF|
|Deucravacitinib|Bristol Myers Squibb|TYK2 inhibitor|Phase II|TYK2|
|ATI-450|Aclaris|MK2 pathway inhibitor|Phase II|MK2|
|ABBV-599|AbbVie|JAK1 + BTK inhibitor|Phase II|JAK1/BTK|
|PF-06650833|Pfizer|IRAK4 inhibitor|Phase II|IRAK4|
|TJ202/MOR202|I-Mab|Anti-CD38 mAb|Phase II|CD38|
|BCD-089|Biocad|IL-6 inhibitor|Phase III|IL-6|

## Osteoarthritis (OA) Pipeline

|Drug Name|Company|Mechanism of Action|Development Phase|Target|
|---|---|---|---|---|
|Lorecivivint|Biosplice Therapeutics|Wnt pathway modulator|Phase III|Wnt pathway|
|Tanezumab|Pfizer/Eli Lilly|NGF inhibitor|Phase III/Regulatory review|NGF|
|CNTX-4975|Centrexion|TRPV1 agonist|Phase III|TRPV1|
|LNA043|Novartis|ANGPTL3 protein|Phase II|Cartilage regeneration|
|MIV-711|Medivir|Cathepsin K inhibitor|Phase II|Cathepsin K|
|SM04690|Samumed|Wnt pathway inhibitor|Phase III|Wnt pathway|
|GLPG1972|Galapagos/Servier|ADAMTS-5 inhibitor|Phase II|ADAMTS-5|
|AMG 570|Amgen|ICOSL and BAFF inhibitor|Phase II|ICOSL/BAFF|
|NE-10|Novartis|IL-17 inhibitor|Phase II|IL-17|
|TPX-100|OrthoTrophix|Matrix protein|Phase II|Cartilage repair|

## Psoriatic Arthritis (PsA) Pipeline

|Drug Name|Company|Mechanism of Action|Development Phase|Target|
|---|---|---|---|---|
|Deucravacitinib|Bristol Myers Squibb|TYK2 inhibitor|Phase III|TYK2|
|Bimekizumab|UCB|IL-17A/IL-17F inhibitor|Phase III|IL-17A/F|
|Sonelokimab|MorphoSys|IL-17A/F nanobody|Phase II|IL-17A/F|
|PF-06650833|Pfizer|IRAK4 inhibitor|Phase II|IRAK4|
|Namilumab|Izana Bioscience|GM-CSF inhibitor|Phase II|GM-CSF|
|BCD-085|Biocad|IL-17 inhibitor|Phase III|IL-17|
|Netakimab|BIOCAD|IL-17 inhibitor|Phase III|IL-17|
|KHK4827|Kyowa Kirin|IL-17 receptor A inhibitor|Phase III|IL-17RA|
|ABY-035|Affibody|IL-17 inhibitor|Phase II|IL-17|
|CC-90006|Bristol Myers Squibb|Anti-PD1 agonist antibody|Phase II|PD1|

## Ankylosing Spondylitis (AS) Pipeline

|Drug Name|Company|Mechanism of Action|Development Phase|Target|
|---|---|---|---|---|
|Bimekizumab|UCB|IL-17A/IL-17F inhibitor|Phase III|IL-17A/F|
|Netakimab|BIOCAD|IL-17 inhibitor|Phase III|IL-17|
|Tofacitinib|Pfizer|JAK inhibitor|Phase III|JAK|
|Upadacitinib|AbbVie|JAK1 inhibitor|Phase III|JAK1|
|Risankizumab|AbbVie|IL-23 inhibitor|Phase III|IL-23|
|Filgotinib|Gilead/Galapagos|JAK1 inhibitor|Phase II|JAK1|
|BCD-085|Biocad|IL-17 inhibitor|Phase III|IL-17|
|Guselkumab|Janssen|IL-23 inhibitor|Phase III/IV|IL-23|
|Izokibep|Affibody/SOBI|IL-17A inhibitor|Phase II|IL-17A|
|Namilumab|Izana Bioscience|GM-CSF inhibitor|Phase II|GM-CSF|

## Disease-Modifying Osteoarthritis Drugs (DMOADs) in Development

|Drug Name|Company|Mechanism of Action|Development Phase|Target|
|---|---|---|---|---|
|Sprifermin|Merck KGaA|Recombinant human FGF18|Phase II|Cartilage growth|
|TPX-100|OrthoTrophix|Matrix protein|Phase II|Cartilage repair|
|TLC599|TLC Biopharmaceuticals|Sustained-release dexamethasone|Phase III|Anti-inflammatory|
|JTA-004|Bone Therapeutics|Hyaluronic acid + plasma proteins|Phase III|Joint lubrication|
|Ampion|Ampio Pharmaceuticals|Anti-inflammatory|Phase III|Multiple inflammatory pathways|
|CNTX-6970|Centrexion|CCR2 antagonist|Phase II|CCR2|
|LNA043|Novartis|ANGPTL3 protein|Phase II|Cartilage regeneration|
|UBX0101|Unity Biotechnology|Senolytic agent|Phase II|Cellular senescence|
|Lorecivivint|Biosplice Therapeutics|Wnt pathway modulator|Phase III|Wnt pathway|
|ATB-346|Antibe Therapeutics|Hydrogen sulfide-releasing NSAID|Phase II|COX/H2S donor|

## Canine Arthritis Treatments in Development

| Drug Name             | Company              | Mechanism of Action        | Development Phase     | Target       |
| --------------------- | -------------------- | -------------------------- | --------------------- | ------------ |
| Librela (bedinvetmab) | Zoetis               | Anti-NGF mAb               | Approved              | NGF          |
| Frunevetmab           | Zoetis               | Anti-NGF mAb               | Approved (Solensia)   | NGF          |
| Grapiprant            | Elanco               | EP4 receptor antagonist    | Approved (Galliprant) | EP4 receptor |
| Ranevetmab            | Nexvet/Zoetis        | Anti-NGF mAb               | Phase III             | NGF          |
| Ralicifeline          | Zoetis               | Anti-NGF mAb (for cats)    | Phase III             | NGF          |
| Robenacoxib           | Elanco               | COX-2 inhibitor            | Approved (Onsior)     | COX-2        |
| AT-016                | Aratana Therapeutics | IL-31 mAb                  | Phase II              | IL-31        |
| CK9-28                | CanineKinetics       | Stem cell therapy          | Phase II              | Multiple     |
| VetStem               | VetStem Biopharma    | Adipose-derived stem cells | Available             | Multiple     |
| Grapiprant            | Elanco               | EP4 receptor antagonist    | Approved              | EP4 receptor |